The only U.S. Food and Drug Administration approved therapy for amblyopia has recently been launched by RevitalVision, LLC, formerly NeuroVision, Inc. Amblyopia, commonly known as “lazy eye”, affects more than an estimated 180 million people worldwide.
The RevitalVision therapy improves amblyopic patients’ vision by enhancing brain processing without drugs, surgery or glasses. During the computer-based training sessions, a series of visual tasks and repetitive images train the brain and improve visual processing. RevitalVision analyzes performance and continuously adjusts the individually customized training sessions to substantially improve vision.
In addition to amblyopia, RevitalVision is clinically and scientifically proven to improve the vision outcomes for post-cataract, post-refractive (LASIK) and presbyopia (need for reading glasses) patients.
“As a Professor, Eye Care Practitioner, and amblyopia patient, I was excited to discover the RevitalVision product and try it for myself. I am thrilled with my results. I am now recommending it to my teenage and adult amblyopia patients who quality for the program to improve their quality of vision,” stated Dr. Peter Shaw-McMinn, O.D., Senior Partner of Sun City Vision Center and Assistant Professor at the Southern California School of Optometry.
On average, RevitalVision’
Older than 9 years of age
Have corrected vision between 20/30 and 20/100
Have minor strabismus (8 prism diopters or less)
Amblyopia patients complete 40, 40-minute sessions and report seeing results in as little as ten sessions. This program is monitored online and allows users to complete the program in the comfort of their home. It is tailored to an individual’s visual needs and paced according to their ability.
The program is professionally monitored throughout completion; however it does requires an eye care professionals’
